News
Release date:2020/12/18 8:24:42
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy due to the lack of early diagnosis and limited response to treatments. It is the most prevalent type of pancreatic neoplasm.

In PDAC, the early onset of hypoxia triggers extracellular matrix remodeling, epithelial to mesenchymal transition, increased cell survival, cancer stem cell formation, and drug resistance. Hypoxia in PDAC is also related to the development of collagen-rich fibrous extracellular matrix (desmoplasia), leading to damaged drug penetration severely. We created polymer nanoparticles (polymersomes) to overcome these difficult challenges, that can target and penetrate pancreatic tumors.

Vitro studies have shown that compared with unencapsulated drugs, under hypoxic conditions, the cellular uptake of polymersomes is higher, and the cytotoxicity of the drug is increased. Compared with the untreated control group, the polymersomes decreased tumor growth in mice by nearly 250% and significantly increased intratumoral necrosis by 60%. It is anticipated that these polymer nanoparticles have considerable translational potential for
drug delivery to solid hypoxic tumors.
 
Targeting the Tumor Core Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors

Source: Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors
at  
https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c00247.
 

Nanomedicine may revolutionize cancer immunotherapy, and the continuous development and optimization of nanomedicine by researchers will inevitably accelerate the application of nanomedicine in cancer immunotherapy. Biochempeg, a leading and reliable PEG supplier that supplies PEG derivatives, monodisperse PEGs, custom PEG derivative synthesis and PEGylation services worldwide. We also supply ADC linkers with small quantity or bulk orders to customers based on their special quality requirements.
 
 

 
Previous:Focus On PROTAC: Summary Of Targets From 2001 To 2019 Next:A New Generation of Cancer Immunotherapy Called "ISAC" Can Achieve Complete Tumor Regression